Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder

Almeida, Carlos Maurício Oliveira de; Brito, Manuelina Mariana Capellari Macruz; Bosaipo, Nayanne Beckmann; Pimentel, Angela Vieira; Tumas, Vítor; Zuardi, Antônio Waldo; Crippa, José Alexandre S; Hallak, Jaime Eduardo Cecílio; Éckeli, Alan Luiz

doi:10.1002/mds.28577

Cited by 44 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results of randomized clinical trials, most of them involving a limited number of patients, have shown the short-term efficacy of the anticholinesterase drugs rivastigmine [67,68] and 5-hydroxytryptophan [75] and the herbal medicine yokukansan [81,82], as well as the lack of efficacy of nelotanserin [74] and cannabidiol [79]. Memantine has shown some degree of medium-term efficacy in the reduction of RBD symptoms in patients with LBD and dementia associated with PD [83].…”

Section: Discussionmentioning

confidence: 99%

“…Cannabidiol is a phytocannabinoid that acts an antagonist of the cannabinoid CB 1 and CB 2 receptors, with a low affinity for them. Following the description of short-term improvements of RBD symptoms in four patients with PD and RBD [78], a randomized placebo-controlled clinical trial involving 33 patients with PD and RBD (level I of evidence; quality score >50%) showed improvement in sleep satisfaction but not significant differences in the control of RBD at two different doses of cannabidiol compared with placebo [79].…”

Section: Cannabinoidsmentioning

confidence: 99%

See 1 more Smart Citation

Current Treatment Options for REM Sleep Behaviour Disorder

Jiménez‐Jiménez

Alonso‐Navarro

García‐Martín

et al. 2021

JPM

View full text Add to dashboard Cite

The symptomatic treatment of REM sleep behaviour disorder (RBD) is very important to prevent sleep-related falls and/or injuries. Though clonazepam and melatonin are usually considered the first-line symptomatic therapy for RBD, their efficiency has not been proven by randomized clinical trials. The role of dopamine agonists in improving RBD symptoms is controversial, and rivastigmine, memantine, 5-hydroxytryptophan, and the herbal medicine yokukansan have shown some degree of efficacy in short- and medium-term randomized clinical trials involving a low number of patients. The development of potential preventive therapies against the phenoconversion of isolated RBD to synucleinopathies should be another important aim of RBD therapy. The design of long-term, multicentre, randomized, placebo-controlled clinical trials involving a large number of patients diagnosed with isolated RBD with polysomnographic confirmation, directed towards both symptomatic and preventive therapy for RBD, is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Cannabinoidsmentioning

confidence: 99%

Current Treatment Options for REM Sleep Behaviour Disorder

Jiménez‐Jiménez

Alonso‐Navarro

García‐Martín

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…Among those, there were seven double-blinded randomised trial results available. Three of the seven assessed the effect of pure CBD on PD symptoms [16][17][18], one study involved treatment with THC and CBD in combination [19], and two papers summarised the results of randomised clinical trials with nabilone [20,21]. Table 1 summarises the findings from the randomised studies.…”

Section: Resultsmentioning

confidence: 99%

“…The authors reported better sleep satisfaction at the 4 th and 8 th weeks in the CBD versus a placebo group with p = 0.049 and p = 0.038 respectively. This effect was, however, transient [16]. Leehey et al [22] also reported improvements in sleep, reflected by SCOPA-sleep change, but no effect of treatment with CBD on RBD.…”

Section: Non-motor Symptoms Of Pd Sleepmentioning

confidence: 97%

Cannabis in Parkinson’s Disease — the patient’s perspective versus clinical trials: a systematic literature review

Figura

Koziorowski

Sławek

2022

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Cannabis and cannabinoids are often considered in the treatment of Parkinson's Disease (PD). The purpose of this paper was to perform a systematic review of the available data on cannabis treatment. We aimed to assess randomised trials as well as surveys among patients. We identified 569 papers on PD and cannabinoid treatment. Of these, there were only seven papers featuring randomised trials on the effects of different cannabinoids on PD. The results of these trials did not support the efficacy of cannabinoids in the treatment of motor signs of PD. Based on the available data, we conclude that there is currently insufficient data to support the administration of cannabinoids to PD patients. Larger, randomised studies of cannabis use in PD should be conducted.

show abstract

“…A subsequent 12-week randomised placebo-controlled trial of CBD for RBD in Parkinson’s disease found it no better than placebo for treating RBD symptoms. 60 De Almeida et al carefully characterised patients with RBD, confirmed the diagnosis by loss of REM atonia and ensured the 33 participants included had a bed partner to monitor RBD activity, which was the primary outcome measure. Participants were randomised to placebo (n = 16) or 75mg to 300mg CBD (n = 17) daily oral capsules, taken in the evening.…”

Section: Effect Of Mixed Cannabinoid Formulations On Insomniamentioning

confidence: 99%

Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far

Maddison¹,

Kosky²,

Walsh³

2022

NSS

View full text Add to dashboard Cite

The legalization of cannabis for medicinal, and in some countries, recreational, purposes in addition to growth in the cannabis industry has meant that cannabis use and interest in the area has increased rapidly over the past 20 years. Treatment of poor sleep and sleep disorders are two of the most common reasons for the current use of medicinal cannabis. However, evidence for the role of medical cannabis in the treatment of sleep disorders has not been clearly established, thus making it challenging for clinicians to make evidence-based decisions regarding efficacy and safety. This narrative review summarizes the highest quality clinical evidence currently available in relation to the use of medicinal cannabis for the treatment of sleep disorders including insomnia, obstructive sleep apnea, restless legs syndrome, rapid eye movement sleep behavior disorder, nightmare disorder and narcolepsy. A summary of the effect of cannabis on sleep quality and architecture is also presented. Currently, there is insufficient evidence to support the routine use of medicinal cannabis as an effective and safe treatment option for any sleep disorder. Nevertheless, emerging evidence is promising and warrants further investigation using standardized cannabinoid products and validated quantitative measurement techniques.

show abstract

Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder

Cited by 44 publications

References 30 publications

Current Treatment Options for REM Sleep Behaviour Disorder

Current Treatment Options for REM Sleep Behaviour Disorder

Cannabis in Parkinson’s Disease — the patient’s perspective versus clinical trials: a systematic literature review

Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far

Contact Info

Product

Resources

About